Lysostaphin: An antistaphylococcal agent

Applied Microbiology and Biotechnology

Volumn 80, Issue 4, 2008, Pages 555-561

  Kumar, Jaspal K ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Lysostaphin; MRSA; Staphylococcus aureus; Therapeutics

Indexed keywords

ANTIBIOTICS; ZINC;

AMIDASE; CELL WALLS; CROSS BRIDGES; GLYCYLGLYCINE; HIGH POTENTIAL; L-ALANINE; LYSOSTAPHIN; METHICILLIN; MRSA; S. AUREUS; STAPHYLOCOCCUS AUREUS; THERAPEUTICS; ZINC METALLOENZYME;

HEALTH;

ERYTHROMYCIN; FOOD PRESERVATIVE; GENTAMICIN; LYSOSTAPHIN; LYSOZYME; MACROGOL; RANALEXIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIUM; CHEMICAL BONDING; ENZYME ACTIVITY; ZINC;

ANTIBIOTIC RESISTANCE; AORTA VALVE; BIOFILM; BURN INFECTION; CATTLE DISEASE; COMBINATION CHEMOTHERAPY; CULTURE MEDIUM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG POTENTIATION; DRUG PURIFICATION; DRUG SAFETY; DRUG STABILITY; ENDOCARDITIS; ENDOPHTHALMITIS; ENZYME ACTIVITY; FOOD CONTROL; FOOD INDUSTRY; FOOD POISONING; GENE MUTATION; HUMAN; IMMUNOGENICITY; KERATITIS; MASTITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NEWBORN INFECTION; NONHUMAN; PHAGOCYTOSIS; SCREENING TEST; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; WOUND INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG STABILITY; HUMANS; LYSOSTAPHIN; PHARMACEUTICAL PREPARATIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 50849108830     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-008-1579-y     Document Type: Short Survey

References (73)

1. GL Archer MW Climo 2001 Staphylococcus aureus bacteremia-consider the source N Eng J Med 344 55 56
2. T Baba O Schneewind 1996 Target cell specificity of a bacteriocin molecule: a C- terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus EMBO J 15 4789 4797
3. A Bera S Herbert A Jakob W Vollmer F Gotz 2005 Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyl-transferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus Mol Microbiol 55 778 787
4. AJ Bramley R Foster 1990 Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary glands Res Vet Sci 49 120 1
5. HP Browder WA Zygmunt JR Young PA Tavorina 1965 Lysostaphin: enzymatic mode of action Biochem Biophys Res Commun 19 383 389
6. BM Buddle MG Cooper 1978 Aspects of the epidemiology of bovine staphylococcal mastitis N Z Vet J 26 296
7. C Cavadini C Hertel WP Hammes 1998 Application of lysostaphin producing lactobacilli to control staphylococcal food poisoning in meat products J Food Prot 61 419 424
8. G Cisani PE Varaldo G Grazi O Soro 1982 High level potentiation of lysostaphin anti-staphylococcal activity by lysozyme Antimicrob Agents Chemother 21 531 535
9. MW Climo RL Patron BP Goldstein GL Archer 1998 Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis Antimicrob Agents Chemother 42 1355 1360
10. M Climo K Ehlert G Archer 2001 Mechanism and suppression of lysostaphin-resistance in oxacillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 45 1431 1437
11. EB Dajcs JJ Hume JM Moreau AR Caballero BM Cannon RJ O'Callaghan 2000 Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit Invest Opthalmol Vis Sci 41 1432 1437
12. JJ Dajcs BA Thibodeaux EB Hume X Zheng GD Sloop RJ O'Callaghan 2001 Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit Curr Eye Res 22 451 457
13. JJ Dajcs BA Thibodeaux DO Girgis MD Shaffer SM Delvisco RJ O'Callaghan 2002 Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit Invest Opthalmol & Visual Sci 43 3712 3716
14. MJ Daley ER Oldham 1992 Lysostaphin immunogenicity of locally administered recombinant protein used in mastitis therapy Vet Immunol Immunopathol 31 301 312
15. B Dassy WT Stringfellow M Lieb JM Fournier 1991 Production of type 5 capsular polysaccharide by Staphylococcus aureus grown in semisynthetic medium J Gen Microbiol 61 1475 1479
16. HP DeHart HE Heath LS Heath PA LeBlanc GL Sloan 1995 The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus staphylolyticus Appl Environ Microbiol 61 1475 1479
17. BLM De Jonge T Didow YS Chang H Labischinski B Berger-Bachi A Gage DA Tomasz 1993 Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus J.Bacteriol 175 2779 2782
18. I Dorner H Blobel W Schaeg 1977 Evaluation of phagocytosis of Staphylococcus aureus with the aid of lysostaphin. (authors translation) Zentral Bakteriol 237 141 146
19. K Ehlert M Tshierske C Mori W Schroder B Berger-Bachi 2000 Site specific serine incorporation by Lif and Epr into positions 3 and 5 of the staphylococcal peptidoglycan interpeptide bridge J Bacteriol 182 2635 2638
20. C Geary M Stevens 1986 Rapid lysostaphin test to differentiate Staphylococcus and Micrococcus species J Clin Microbiol 23 1044 1045
21. S Graham PJ Coote 2007 Portent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin J Antimicrob Chemother 59 759 762
22. A Grundling O Schneewind 2006 Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus J Bacteriol 188 2463 2472
23. EF Harrison ME Fuquay WA Zygmunt 1975 Antigenic response to topically applied proteins Infec Immun 11 309 312
24. LS Heath HE Heath GL Sloan 1987 Plasmid encoded lysostaphin endopeptidase gene of Staphylococcus simulans biovar. staphylolyticus FEMS Microbiol Lett 44 129 133
25. P Heinrich R Rosenstein M Bohmer P Sonner F Gotz 1987 The molecular organization of the lysostaphin gene and its sequence repeated in tandem Mol Gen Gent 209 563 569
26. JN Huan 1992 Topical use of lysostaphin for Staphylococcus aureus infection of burn wounds in mice Zhoughua Wai Ke Za Zhi 30 270 271
27. JN Huan YL Chen SD Ge 1994 Methicillin-resistant Staphylococcus aureus infection and its treatment in burned patients Zhoughua Wai Ke Za Zhi 32 244 245
28. JN Huan Y Han YL Chen 1995 Effect of lysostaphin on phagocyte function in burn mice Zhoughua Xing Shao Shang Wai ke Za Zhi 11 255 257
29. MM Huber TW Huber 1989 Susceptibility of methicillin-resistant Staphylococcus aureus to lysostaphin J Clin Microbiol 27 1122 1124
30. OJ Iversen A Grov 1973 Studies on lysostaphin Eur J Biochem 38 293 300
31. KK Jaspal KS Arun PR Kulkarni 2001 A simple turbidometric method for the detection of S. aureus Int J Food Sci Nut 52 235 241
32. BF King ML Biel BJ Wilkinson 1980 Facile penetration of the Staphylococcus aureus capsule by lysostaphin Infect Immun 29 892 896
33. RG Knight DM Shales 1983 Rapid identification of Staphylococcus aureus and Streptococcus pneumoniae from blood cultures J Clin Microbiol 17 97 99
34. JF Kokai-Kun SM Walsh T Chanturiya JJ Mond 2003 Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model Antimicrob Agents Chemother 47 1589 1597
35. JF Kokai-Kun T Chanturiya JJ Mond 2007 Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model J Antimicrob Chemother 60 1051 1059
36. U Kopp M Roos J Wencke H Labischinski 1996 Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target? Microb Drug Resist 2 29 41
37. C Kusuma A Jadanova T Chanturiya JF Kokai-kun 2007 Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo Antimicrob Agents Chemother 51 475 82
38. TE Long 2003 Recent progress toward the clinical development of new anti-MRSA antibiotics IDrugs 6 351 359
39. FD Lowy 1998 Staphylococcus aureus infections N Eng J Med 339 520 532
40. H Maidhof B Reinicke P Blumel B Berger-Bachi H Labischinski 1991 femA, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains J Bacteriol 173 3506 3513
41. I Marova V Dadak 1993 Modified simplified method for isolation of lysostaphin from the culture filtrate of Staphylococcus staphylolyticus Folia Microbiol 38 245 252
42. JS McDonald 1977 Streptococcal and staphylococcal mastitis Am Vet Med Assoc 170 1157 1159
43. I Mierau P Leij SI Van B Blommestein E Floris J Mond EJ Smid 2005 Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the use of lysostaphin Microb Cell Fact 27 4 15
44. ER Oldham MJ Daley 1991 Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic J Dairy Sci 74 4175 4182
45. O Oluola L Kong M Fein LE Weisman 2007 Lysostaphin in treatment of neonatal Staphylococcus aureus infection Antimicrob Agents Chemother 51 2198 200
46. K O'Riordan JC Lee 2004 Staphylococcus aureus capsular polysaccharides Clin Microbiol Rev 17 218 334
47. RL Patron MW Climo BP Goldstein GL Archer 1999 Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin Antimicrob Agents Chemotherapy 43 1754 1755
48. J Polak LP Della P Blachburn 1993 In vitro activity of recombinant lysostaphin-antibiotic combinations towards methicillin-resistant Staphylococcus Diag Microbiol Infect Dis 17 265 270
49. B Poutrel JP Caffin 1981 Lysostaphin disk test for routine presumptive identification of Staphylococci J Clin Microbiol 13 1023 1025
50. BF Poutrel FB Gilbert M Lebrun 1995 Effects on culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains Clin Diagn Lab Immunol 2 166 171
51. PA Recsei AD Gruss RP Novick 1987 Cloning, sequence and expression of the lysostaphin gene from Staphylococcus simulans Proc Natl Acad Sci USA 84 1127 1131
52. AF Rizzo H Korkeala 1984 Improvements in the lipid extraction of Staphylococcal cells by lysostaphin treatment Biochem Biophys Acta 792 367 370
53. CA Schindler VT Schuhardt 1964 Lysostaphin: a new bacteriolytic agent for the Staphylococcus Proc Natl Acad Sci USA 51 414 421
54. CA Schindler VT Shuhradt 1965 Purification and proper lysostaphin A lytic agent for Staphylococcus aureus Biochem Biophys 97 242 250
55. PJ Sevarance CA Kauffman JN Sheagren 1980 Rapid identification of Staphylococcus aureus by using lysostaphin sensitivity J Clin Microbiol 11 724 727
56. A Shrinivasan JD Dick TM Perl 2002 Vancomycin resistance in Staphylococci Clin Microbiol Rev 15 430 438
57. TL Smith ML Pearson KR Wilcox C Cruz MV Lancaster B Robinson-Dunn FC Tenover MJ Zrevos JD Band E White WR Jarvis 1999 Emergence of vancomycin resistance in Staphylococcus aureus N Eng J Med 340 493 501
58. WH Sperber 1976 The identification of Staphylococci in clinical and food microbiology laboratories CRC Crit Rev Clin Lab Sci 7 121 124
59. W Steuden S Szymanice 1988 Removal of surface adherent Staphylococcus aureus in the determination of phagocytosis and intracellular killing by the use of lysostaphin Arch Immunol Ther Exp (Warsz) 36 633 637
60. AM Stranden K Ehlert H Labischinski B Berger-Bachi 1997 Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus J Bacteriol 179 9 16
61. WT Stringfellow B Dassy M Lieb JM Fournier 1991 Staphylococcus aureus growth and type 5 capsular polysaccharide production in synthetic media Appl Environ Microbiol 57 618 621
62. JL Strominger JM Ghuysen 1967 Mechanism of enzymatic bacteriolysis Science 156 213 221
63. M Sugei T Fugiwara H Ohta M Komatsuzawa M Ohara H Suginaka 1997 epr which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus J.Bacteriol 179 4311 4318
64. VI Surovtsev TV Fedorov MA Borozdina 2004 Michaelis-Menten kinetics for determining enzymatic activity of lysostaphin Biochemistry 69 754 756
65. P Szweda R Pladzyk R Kotlowski J Kur 2001 Cloning, expression and purification of the Staphylococcus simulans lysostaphin using the intein-chitin-binding domain (CBD) system Protein Expr Purif 22 467 471
66. HR Trayer CE Buckley III 1970 Molecular properties of lysostaphin a bacteriolytic agent specific for Staphylococcus aureus J Biochem 245 4842 4846
67. EU Tuncan SE Martin 1987 Lysostaphin lysis procedure for detection of Staphylococcus aureus by the firefly bioluminescent ATP method Appl Environ Microbiol 53 88 91
68. T Wadstrom O Vesterberg 1971 Studies on endo acetylglucosaminidase staphylolytic peptidase and N-acetyl muramyl-l-alanine amidase in lysostaphin and from Staphylococcus aureus Acta Pathol Microbiol Scand 1379 248 264
69. E Walencka B Sadowska S Rozalska W Hryniewicz B Rozalska 2005 Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication Pol J Microbiol 54 191 200
70. S Walsh A Shah J Mood 2002 Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol Antimicrob Agents Chemother 47 554 558
71. JA Wu C Kusuma JJ Mond JF Kokai-Kun 2003 Lysoataphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces Antimicrob Agents Chemother 47 3407 3414
72. R Zhou S Chen P Recei 1988 A dye release assay for determination of lysostaphin activity Anal Biochem 171 141 144
73. WA Zygmunt PA Tavormina 1972 Lysostaphin: model for a specific enzymatic approach to infectious disease Prog Drug Res 16 309 333